申请人:SHANGHAI XINGYE PHARMACEUTICAL TECHNOLOGY CO., LTD
公开号:US20210221812A1
公开(公告)日:2021-07-22
The present invention disclosed a series of novel matrine α-ketoamine derivatives as shown in formula I, which could inhibit the overexpression of TNF-α and/or activate the immune killing function of the NK cells, thus could be used to treat autoimmune diseases, inflammatory diseases, neurodegenerative diseases and tumors mediated by the abnormal levels of TNF-α and/or NK cell dysfunction.
本发明公开了一系列如公式I所示的新型苦参碱α-酮胺衍生物,它们能够抑制TNF-α的过度表达和/或激活自然杀伤(NK)细胞的免疫杀伤功能,因此可用于治疗由TNF-α水平异常和/或NK细胞功能障碍介导的自身免疫性疾病、炎症性疾病、神经退行性疾病和肿瘤。